The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis
- PMID: 17086903
- DOI: 10.1177/1352458506070620
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis
Abstract
We evaluated the risk of worsening according to the length of exposure to interferon beta (IFNbeta) in a large cohort of 2090 multiple sclerosis patients collected by the Italian MS Database Network. Overall 44,140 patient-visits with a follow-up of 22,143 patient-years were evaluated. Forty-one per cent of patients were exposed to IFNbeta for up to 2 years, 39% for 2-4 years and 20% for more than 4 years. A Cox regression model was used to analyse two clinical outcomes: disability progression and worsening of relapse rate. The technique of propensity score was applied to reduce bias in the comparison of non-randomized groups. The risks of disability progression (HR =0.23; 95% CI: 0.17-0.30) and worsening of relapse rate (HR =0.19; 95% CI: 0.14-0.27) were reduced by about 4-5-fold in patients exposed to IFNbeta for more than four years, compared with patients exposed for up to two years. The propensity score technique confirmed the findings. The proportion of days covered by IFNbeta treatment was lower (P <0.0001) in patients exposed to IFNbeta for up to two years than in other groups. A clinical stabilization over two years of IFNbeta exposure may predict a subsequent good clinical response to treatment.
Similar articles
-
Italian Multiple Sclerosis Database Network.Neurol Sci. 2006 Sep;27 Suppl 5:S358-61. doi: 10.1007/s10072-006-0694-8. Neurol Sci. 2006. PMID: 16998720
-
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16. J Neurol Sci. 2009. PMID: 19615696 Clinical Trial.
-
Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.J Eval Clin Pract. 2004 Nov;10(4):511-8. doi: 10.1111/j.1365-2753.2003.00436.x. J Eval Clin Pract. 2004. PMID: 15482413
-
Interferon after 10 years in patients with multiple sclerosis.Neurol Sci. 2006 Sep;27 Suppl 5:S369-72. doi: 10.1007/s10072-006-0697-5. Neurol Sci. 2006. PMID: 16998723 Review.
-
Interferon Beta: From Molecular Level to Therapeutic Effects.Int Rev Cell Mol Biol. 2016;326:343-72. doi: 10.1016/bs.ircmb.2016.06.001. Epub 2016 Jul 20. Int Rev Cell Mol Biol. 2016. PMID: 27572132 Review.
Cited by
-
Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study).Patient Prefer Adherence. 2018 Apr 19;12:569-575. doi: 10.2147/PPA.S154417. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 29720872 Free PMC article.
-
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2. BMC Neurol. 2016. PMID: 27416843 Free PMC article.
-
The Italian multiple sclerosis register.Neurol Sci. 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13. Neurol Sci. 2019. PMID: 30426289 Free PMC article.
-
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.PLoS One. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. Print 2013. PLoS One. 2013. PMID: 23704913 Free PMC article. Clinical Trial.
-
Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.PLoS One. 2011;6(10):e26568. doi: 10.1371/journal.pone.0026568. Epub 2011 Oct 25. PLoS One. 2011. PMID: 22046309 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical